Mark Ingham's high conviction buy call: Ever expensive Aspen suddenly cheap

After peaking at almost R450 early last year, the share price of Aspen Pharmacare has since been in steady retreat and is currently trading below R300. But while traders have been seeking shelter, independent investment analyst Mark Ingham is attracted by Mr Market's depression. He now regards Aspen shares as an excellent buying opportunity, rating his call as "high conviction". Ingham puts Aspen's fair value at R390 a share which means the current price offers today's buyers a significant margin of safety. In this in-depth interview Ingham unpacks the attraction of the R130bn market cap stock which has grown into a multinational operation with only around one fifth of its business in South Africa.